Page last updated: 2024-12-11

furanoheliangolide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

furanoheliangolide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5358393
CHEMBL ID371358
SCHEMBL ID7996210
MeSH IDM0483636

Synonyms (14)

Synonym
nsc249918
nsc-249918
goyazensolide
60066-35-5
furanoheliangolide
CHEMBL371358
goiazensolide
2-propenoic acid, 2-methyl-, 2,3,3a,4,5,6,7,11a-octahydro-10- (hydroxymethyl)-6-methyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca(b)furan-4-yl ester, (3ar,3ar*,4s*,6r*,10z,11ar*))-
nsc 249918
bdbm50433423
SCHEMBL7996210
(3ar,4s,6r,11ar,z)-10-(hydroxymethyl)-6-methyl-3-methylene-2,7-dioxo-2,3,3a,4,5,6,7,11a-octahydro-6,9-epoxycyclodeca[b]furan-4-yl methacrylate
[(2z,4r,8r,9s,11r)-2-(hydroxymethyl)-11-methyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] 2-methylprop-2-enoate
DTXSID701317740

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcriptional activator MybGallus gallus (chicken)IC50 (µMol)0.62760.62522.76989.5499AID746038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC100 (µMol)20.000010.000010.000010.0000AID242927
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)IC100 (µMol)20.000010.000010.000010.0000AID242927
Transcription factor p65Homo sapiens (human)IC100 (µMol)20.00005.00009.000010.0000AID242927; AID262798
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (109)

Processvia Protein(s)Taxonomy
regulation of gene expressionTranscriptional activator MybGallus gallus (chicken)
mitotic cell cycleTranscriptional activator MybGallus gallus (chicken)
positive regulation of transcription by RNA polymerase IITranscriptional activator MybGallus gallus (chicken)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
follicular dendritic cell differentiationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
germinal center formationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
extracellular matrix organizationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to lipopolysaccharideNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
rhythmic processNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
spleen developmentNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
protein bindingTranscriptional activator MybGallus gallus (chicken)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscriptional activator MybGallus gallus (chicken)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscriptional activator MybGallus gallus (chicken)
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
protein bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleoplasmTranscriptional activator MybGallus gallus (chicken)
nucleusTranscriptional activator MybGallus gallus (chicken)
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytosolNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
chromatinNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
Bcl3/NF-kappaB2 complexNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID1349842Induction of apoptosis in human EOL-1 cells assessed as necrotic cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0.032%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349839Induction of apoptosis in human EOL-1 cells assessed as live cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 97.5%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349846Induction of apoptosis in human EOL-1 cells assessed as necrotic cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0.032%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1557479Antiproliferative activity against mouse Sch10545 cells incubated for 72 hrs by resazurin dye based fluorescence assay2019Journal of natural products, 03-22, Volume: 82, Issue:3
Potential Anticancer Agents Characterized from Selected Tropical Plants.
AID746037Cytotoxicity against chicken HD11 cells assessed as cell viability after 24 hrs by MTS assay2013European journal of medicinal chemistry, May, Volume: 63Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: structure-activity relationships.
AID1349783Induction of apoptosis in human MOLM13 cells assessed as live cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 86.8%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349779Induction of apoptosis in human MOLM13 cells assessed as live cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 86.8%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349788Induction of apoptosis in human MOLM13 cells assessed as early apoptotic cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 11.8%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1417094Inhibition of recombinant oligo-histidine-tagged Leishmania major DHODH expressed in Escherichia coli BL21(DE3) cells using DHO as substrate measured after 60 secs2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID713894Antimycobacterial activity against Mycobacterium tuberculosis H37Ra2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in antitubercular natural products.
AID1417097Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 1000 uM by differential scanning fluorimetry-based ThermoFMN assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417100Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 1000 uM by SYPRO orange dye-based differential scanning fluorimetry2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1862054Antiviral activity against drug treated Influenza A virus strain A/Netherlands/604/2009 cell lysate infected in dog MDCK cells assessed as reduction in viral replication at 1 uM and measured after 8 hr by crystal violet staining based plaque assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Withaferin A, a polyfunctional pharmacophore that includes covalent engagement of IPO5, is an inhibitor of influenza A replication.
AID242927Concentration required for complete inhibition of Nuclear factor kappa B DNA binding2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB.
AID1349849Induction of apoptosis in human EOL-1 cells assessed as late apoptotic cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0.535%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349776Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1862045Competitive binding affinity to human annexin A2 in human A549 cell lysate at 10 uM for 30 mins followed by GOYA-P treatment for 30 mins by DTB-Cy3 dye based SDS-PAGE analysis2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Withaferin A, a polyfunctional pharmacophore that includes covalent engagement of IPO5, is an inhibitor of influenza A replication.
AID1349843Induction of apoptosis in human EOL-1 cells assessed as live cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 97.5%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1417095Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 100 uM by differential scanning fluorimetry-based ThermoFMN assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID746038Inhibition of c-Myb-induced mim-1 gene expression in doxycyclin-treated chicken HD11 cells after 24 hrs by GFP assay2013European journal of medicinal chemistry, May, Volume: 63Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: structure-activity relationships.
AID1349847Induction of apoptosis in human EOL-1 cells assessed as live cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 97.5%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1557468Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability2019Journal of natural products, 03-22, Volume: 82, Issue:3
Potential Anticancer Agents Characterized from Selected Tropical Plants.
AID1862046Competitive binding affinity to human IPO5 in human PC-3 cell lysate at 10 uM for 30 mins followed by GOYA-P treatment for 30 mins by DTB-Cy3 dye based SDS-PAGE analysis2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Withaferin A, a polyfunctional pharmacophore that includes covalent engagement of IPO5, is an inhibitor of influenza A replication.
AID1417099Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 500 uM by SYPRO orange dye-based differential scanning fluorimetry2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1349899Induction of apoptosis in human MOLM13 cells assessed as caspase-3 activation at 10 uM after 72 hrs by immunoblotting analysis2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349778Synergistic antileukemic activity against human EOL-1 cells assessed as concentration required for <= 75% cell survival after 72 hrs in presence of midostaurin by CellTiter 96 AQueous One solution cell proliferation assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349777Synergistic antileukemic activity against human MOLM13 cells assessed as concentration required for <= 75% cell survival after 72 hrs in presence of midostaurin by CellTiter 96 AQueous One solution cell proliferation assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1417116Antileishmanial activity against Leishmania donovani amastigotes2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1349775Cytotoxicity against human EOL-1 cells after 72 hrs by MTS assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1862058Competitive binding affinity to human Vimentin in human PC-3 cell lysate at 10 uM for 30 mins followed by WA-P2 treatment for 30 mins by SDS gel Cy3 fluorescence based MS/MS analysis2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Withaferin A, a polyfunctional pharmacophore that includes covalent engagement of IPO5, is an inhibitor of influenza A replication.
AID1349848Induction of apoptosis in human EOL-1 cells assessed as early apoptotic cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 1.94%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID262798Inhibition of NF-kappaB DNA binding by EMSA2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks.
AID1417101Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1349840Induction of apoptosis in human EOL-1 cells assessed as early apoptotic cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 1.94%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349785Induction of apoptosis in human MOLM13 cells assessed as late apoptotic cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 1.43%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349789Induction of apoptosis in human MOLM13 cells assessed as late apoptotic cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 1.43%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349841Induction of apoptosis in human EOL-1 cells assessed as late apoptotic cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0.535%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349784Induction of apoptosis in human MOLM13 cells assessed as early apoptotic cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 11.8%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1417098Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 100 uM by SYPRO orange dye-based differential scanning fluorimetry2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1349782Induction of apoptosis in human MOLM13 cells assessed as necrotic cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349903Inhibition of NFkappaB p65 in human MOLM13 cells at 10 uM after 72 hrs by immunoblotting method2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349787Induction of apoptosis in human MOLM13 cells assessed as live cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 86.8%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349780Induction of apoptosis in human MOLM13 cells assessed as early apoptotic cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 11.8%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1557480Antiproliferative activity against human Ben-Men-1 cells incubated for 72 hrs by resazurin dye based fluorescence assay2019Journal of natural products, 03-22, Volume: 82, Issue:3
Potential Anticancer Agents Characterized from Selected Tropical Plants.
AID1349900Induction of apoptosis in human EOL-1 cells assessed as caspase-3 activation at 10 uM after 72 hrs by immunoblotting analysis2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349845Induction of apoptosis in human EOL-1 cells assessed as late apoptotic cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0.535%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349790Induction of apoptosis in human MOLM13 cells assessed as necrotic cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349781Induction of apoptosis in human MOLM13 cells assessed as late apoptotic cells at 0.56 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 1.43%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1417102Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1349774Cytotoxicity against human MOLM13 cells after 72 hrs by MTS assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349844Induction of apoptosis in human EOL-1 cells assessed as early apoptotic cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 1.94%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349850Induction of apoptosis in human EOL-1 cells assessed as necrotic cells at 2.8 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0.032%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1862057Competitive binding affinity to human Vimentin in human PC-3 cell lysate at 10 uM for 30 mins followed by WA-P1 treatment for 30 mins by SDS gel Cy3 fluorescence based MS/MS analysis2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Withaferin A, a polyfunctional pharmacophore that includes covalent engagement of IPO5, is an inhibitor of influenza A replication.
AID1349786Induction of apoptosis in human MOLM13 cells assessed as necrotic cells at 1.1 uM after 24 hrs by Annexin-V FITC/7-AAD staining based flow cytometric method (Rvb = 0%)2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1349904Inhibition of NFkappaB p65 in human EOL-1 cells at 10 uM after 72 hrs by immunoblotting method2018Journal of natural products, 03-23, Volume: 81, Issue:3
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
AID1862055Antiviral activity against drug treated Influenza A virus strain A/Netherlands/604/2009 cell lysate infected in dog MDCK cells assessed as reduction in viral replication at 500 nM and measured after 8 hr by crystal violet staining based plaque assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Withaferin A, a polyfunctional pharmacophore that includes covalent engagement of IPO5, is an inhibitor of influenza A replication.
AID243231Concentration required for complete inhibition of Nuclear factor kappa B DNA binding2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB.
AID1862053Cytotoxicity against human A549 cells assessed as reduction in cell viability at 1 uM for 10 hrs by Hoechst 33342 staining based fluorescence microscopy2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Withaferin A, a polyfunctional pharmacophore that includes covalent engagement of IPO5, is an inhibitor of influenza A replication.
AID1417096Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 500 uM by differential scanning fluorimetry-based ThermoFMN assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (20.00)29.6817
2010's14 (56.00)24.3611
2020's6 (24.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.75 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (92.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]